Sagimet Biosciences shares are trading higher. The company on Friday announced that results from the Phase 2b FASCINATE-2 clinical trial of denifanstat versus placebo in biopsy-confirmed metabolic-dysfunction associated steatohepatitis patients with stage 2 or stage 3 fibrosis were published in The Lancet Gastroenterology & Hepatology.
Portfolio Pulse from Benzinga Newsdesk
Sagimet Biosciences shares rose after announcing positive Phase 2b trial results for denifanstat in treating metabolic-dysfunction associated steatohepatitis, supporting its advancement to Phase 3.
October 14, 2024 | 4:05 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Sagimet Biosciences shares increased following the publication of positive Phase 2b trial results for denifanstat, indicating significant improvements in treating MASH and supporting Phase 3 development.
The publication of positive trial results in a reputable journal like The Lancet can boost investor confidence, leading to a rise in stock price. The results showing significant improvements in disease activity and fibrosis resolution are crucial for advancing to Phase 3, which is a positive development for the company.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100